GlassScriptPhysician profile
Magdalene Marfo
NPI 1992776330
$4,996.18
in general payments reported to CMS, 2019-2025
39 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $685 · 2021: $669 · 2022: $1,038 · 2023: $1,227 · 2024: $762 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,261.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $791.26 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $553.86 | 2021-2024 | |
| Lilly USA, LLC | $542.62 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $462.32 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $431.49 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $259.60 | 2022 | |
| Novo Nordisk INC | $204.29 | 2019-2024 | Rybelsus, Ozempic |
| Allergan, INC. | $189.87 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $181.11 | 2022-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.29 | 2021-2024 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.91 | 2020-2024 | Jardiance |
| Viiv Healthcare Company | $121.83 | 2023 | Dovato |
| Stryker Corporation | $119.97 | 2023 | Mako |
| Glaxosmithkline, LLC. | $102.60 | 2025 | Arexvy |
| Redhill Biopharma INC. | $75.37 | 2020-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdalene Marfo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.